Antibody Drug Conjugates: Technologies and Global Markets
15 Oct, 2014, 12:53 ET
LONDON, Oct. 15. 30, 2014 /PRNewswire/ -- REPORT HIGHLIGHTS
The global market for ADC drugs reached $179 million in 2012 and $396 million in 2013. The market should reach $2.8 billion in 2018 with a compound annual growth rate (CAGR) of 48.1%.
This report provides:
An overview of the global market for ADCs as a part of the pharmaceutical industry that is looking for innovative technologies.
Analyses of global market trends, with data from 2012, 2013, and projections of compound annual growth rates (CAGRs) through 2018.
Examination of key market drivers and challenges.
Insight into regulatory hurdles and how to meet them, as well as discussion of the drugs (and the companies behind them) that have received approval.
As the pharmaceutical industry grows, it is trying to find more ways to successfully combat disorders and disease, whether through different chemistries with novel mechanisms of action or new therapeutic areas. Companies realize they can only survive for so long by creating similar drugs to competitors where, for example, market share might be shared or by acquiring or merging with competitors. Indeed, effective companies realize they might find new ways of running their businesses at their core and that is through the science behind their products.Antibody drug conjugates (ADCs) represent that new science and turf that pharmaceutical companies want. They are attractive too because they are targeted to certain cells, sparing other tissue and reducing side effects. ADCs consist of the merging by technology, which will be described in the report, of a monoclonal antibody (mAb), a linker and some sort of cytotoxic agent that kills that which it is designed to. The drug, because it is an antibody, binds to an antigen and induces an immune response, but it also contains a cytotoxin for the selected area, enabling a greater kill effect.
STUDY GOAL AND OBJECTIVES
The present study meets this need by focusing on the global market for ADCs in light of the most recent available information. In addition to looking at future and current markets for a wide variety of new, reformulated and established products, the study will analyze technological, environmental, legal/regulatory and socioeconomic developments that may influence the market for ADC drugs.This report provides an analysis of the emerging ADC industry and markets, geographically and by therapeutic area. The future of ADC drugs will also be discussed.The following topics will be discussed in the report:
The technology and where it fits into the pharmaceutical industry.
The key drivers and challenges.
Key considerations including regulatory hurdles.
Analysis of commercialized ADCs and those in the development pipeline.
Analysis of development and alliance deals.
Summaries of companies in the ADC industry.
Financial sales figures and projections out to 2018 including compound annual growth rates (CAGRs) will appear for the aforementioned information.
The report has been written for the entire pharmaceutical community but is tailored especially for readers with an interest in the marketing, management and public policy dimensions of ADC drugs, including readers in the following:
The pharmaceuticals industry, especially companies planning to enter this field.
Medial research institutions.
International organizations and governmental organizations with relevant responsibilities such as health, drug safety, conservation and the environment, and foreign trade.
The financial and analyst community.
SCOPE OF REPORT
This report is an analytical business tool whose primary purpose is to describe the ADC drug industry.For the purposes of this report, commercialized ADCs are those drugs that are approved by the U.S. Food and Drug Administration (FDA) as new drugs that are not sold only as monoclonal antibodies (mAbs). The study's main focus is on legal, prescription-required therapeutic medicines sold in the open market. For this report, the form of an ADC involving an antibody and small-molecule cytotoxin will be viewed as the ADC of today, though acknowledgement is made in this report that ADCs will expand to encompass other forms of small-molecule drugs possibly in nanoparticle size or some other type.The study also does not cover the following: mAbs that do not contain a linker and cytotoxic agent and, thus, do not constitute an ADC; however, novel ADC technology and novel ADC-related technology will be discussed.
Again, the format of the study is organized around the following topics:
Major types and applications of ADC drugs.
Market size and segmentation, including breakdown of sales by therapeutic area and geographic area.
Market projections through 2018.
Observations and conclusions regarding the future of the industry.
METHODOLOGY AND INFORMATION SOURCES
Both primary and secondary research methods were used in preparing this research report. The findings and conclusions contained in this report are based on information gathered from development companies and sales and manufacturers involved with primarily the ADC industry, as defined by the U.S. FDA, and secondarily the larger world of antibody drugs. Additional data were obtained from extensive reviews of secondary sources such as trade publications, trade associations, company literature and online databases.
Download the full report: https://www.reportbuyer.com/product/2042686/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Share this article